Release Date: 11-Feb-2025
In 2024, Elrexfio, a bispecific antibody developed by Pfizer for multiple myeloma, achieved sales of US$ 133 million, marking an increase of over 1,200% from its 2023 sales of approximately US$ 10 million. This represents one of the biggest growth surges in the bispecific antibody market, reflecting strong demand and expanding clinical adoption. The significant sales jump highlights Elrexfio’s increasing presence in the multiple myeloma treatment landscape, driven by its novel mechanism and growing prescriber confidence. Its rapid commercial success further strengthens Pfizer’s position in the competitive oncology space, particularly in the emerging bispecific antibody market.
For Global Bispecific Antibodies Report Sample Contact [email protected]